Trial Outcomes & Findings for Randomized Controlled Trial of CES for Fibromyalgia (NCT NCT04115033)

NCT ID: NCT04115033

Last Updated: 2026-05-22

Results Overview

For subjects with fibromyalgia, clinical pain was assessed in both groups using the Defense Veterans Pain Rating Scale (DVPRS), a validated measurement tool for pain, as well as analgesic consumption. Clinical pain was measured at baseline, 6 weeks following treatment, and 12 weeks following treatment completion in both groups. Mean differences were measured between the baseline score and the 12-week score. The DVPRS is a combination of several different pain scales including the VAS, verbal rating scale, FACES scale, and numerical rating scale. Measurements will be graded on a scale of 0-10 with 0 being "no pain" and 10 being "severe" or "worst pain."

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

50 participants

Primary outcome timeframe

baseline, 6 weeks into treatment, and 12 weeks post treatment

Results posted on

2026-05-22

Participant Flow

Veterans were recruited through direct referrals from Atlanta VA Healthcare System physicians, and through letters and phone calls inviting them to participate following a data access request through the VA corporate data warehouse based on a diagnosis of fibromyalgia and other characteristics matching inclusion criteria for the study.

A total of 50 participants were consented for this study. Two of these participants could not begin the study due to MRI-incompatible medical device/metal implants. These two individuals were excluded from the study after initial consent and prior to randomization. A total of 48 participants were randomly allocated to treatment groups.

Participant milestones

Participant milestones
Measure
True CES Device/Treatment
Participants received active stimulation using a CES device that was pre-set to a microcurrent of less than 0.5 mA and were instructed to use the device for 60 minutes per day for 12 weeks.
Sham CES Device/Treatment
Participants received a device that was identical in appearance to the true CES device and turned on and counted down with a 60 minute timer in the same manner as an active device, but delivered no stimulation. They were instructed to use the device for 60 minutes per day for 12 weeks.
Overall Study
STARTED
25
23
Overall Study
COMPLETED
17
16
Overall Study
NOT COMPLETED
8
7

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Randomized Controlled Trial of CES for Fibromyalgia

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
True CES Device/Treatment
n=25 Participants
Participants received active stimulation using a CES device that was pre-set to a microcurrent of less than 0.5 mA and were instructed to use the device for 60 minutes per day for 12 weeks.
Sham CES Device/Treatment
n=23 Participants
Participants received a device that was identical in appearance to the true CES device and turned on and counted down with a 60 minute timer in the same manner as an active device, but delivered no stimulation. They were instructed to use the device for 60 minutes per day for 12 weeks.
Total
n=48 Participants
Total of all reporting groups
Sex: Female, Male
Female
15 Participants
n=2 Participants
18 Participants
n=4 Participants
33 Participants
n=6 Participants
Sex: Female, Male
Male
10 Participants
n=2 Participants
5 Participants
n=4 Participants
15 Participants
n=6 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=2 Participants
0 Participants
n=4 Participants
0 Participants
n=6 Participants
Race (NIH/OMB)
Asian
0 Participants
n=2 Participants
0 Participants
n=4 Participants
0 Participants
n=6 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=2 Participants
0 Participants
n=4 Participants
0 Participants
n=6 Participants
Race (NIH/OMB)
Black or African American
17 Participants
n=2 Participants
15 Participants
n=4 Participants
32 Participants
n=6 Participants
Race (NIH/OMB)
White
7 Participants
n=2 Participants
8 Participants
n=4 Participants
15 Participants
n=6 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=2 Participants
0 Participants
n=4 Participants
0 Participants
n=6 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants
n=2 Participants
0 Participants
n=4 Participants
1 Participants
n=6 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants
n=2 Participants
0 Participants
n=4 Participants
1 Participants
n=6 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
24 Participants
n=2 Participants
23 Participants
n=4 Participants
47 Participants
n=6 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=2 Participants
0 Participants
n=4 Participants
0 Participants
n=6 Participants
Age, Continuous
49.8 Years
n=2 Participants
49.4 Years
n=4 Participants
49.6 Years
n=6 Participants
Defense & Veterans Pain Rating Scale (DVPRS)
6.6 Score on scale
n=2 Participants
6.8 Score on scale
n=4 Participants
6.7 Score on scale
n=6 Participants

PRIMARY outcome

Timeframe: baseline, 6 weeks into treatment, and 12 weeks post treatment

For subjects with fibromyalgia, clinical pain was assessed in both groups using the Defense Veterans Pain Rating Scale (DVPRS), a validated measurement tool for pain, as well as analgesic consumption. Clinical pain was measured at baseline, 6 weeks following treatment, and 12 weeks following treatment completion in both groups. Mean differences were measured between the baseline score and the 12-week score. The DVPRS is a combination of several different pain scales including the VAS, verbal rating scale, FACES scale, and numerical rating scale. Measurements will be graded on a scale of 0-10 with 0 being "no pain" and 10 being "severe" or "worst pain."

Outcome measures

Outcome measures
Measure
Sham CES Device/Treatment
n=16 Participants
Participants received a device that was identical in appearance to the true CES device and turned on and counted down with a 60 minute timer in the same manner as an active device, but delivered no stimulation. They were instructed to use the device for 60 minutes per day for 12 weeks.
True CES Device/Treatment
n=17 Participants
Participants received active stimulation using a CES device that was pre-set to a microcurrent of less than 0.5 mA and were instructed to use the device for 60 minutes per day for 12 weeks.
Clinical Pain Change
Change at 6-Week Timepoint
-1.75 Change (from baseline) in DVPRS score
Standard Deviation 1.92
-0.97 Change (from baseline) in DVPRS score
Standard Deviation 1.74
Clinical Pain Change
Change at 12-Week Timepoint
-2.00 Change (from baseline) in DVPRS score
Standard Deviation 1.97
-1.38 Change (from baseline) in DVPRS score
Standard Deviation 1.80

SECONDARY outcome

Timeframe: baseline, 6 weeks into treatment, and 12 weeks post treatment (change from baseline to 12 weeks post reported)

The region of interest (ROI) was the right Cerebellar 7b seed, and a 2x2 mixed ANOVA interaction was conducted with Family -Wise Error (FWE) constraints to control for multiple comparisons. Voxel threshold was set to p\<0.005 uncorrected, cluster threshold of p\<0.05 FWE corrected. A Fisher-transform z-score represents the mean connectivity values for each covariate in the model (i.e. groups) for each significant cluster. A z-score value of 0 indicates no difference in functional connectivity. Positive z-scores denote stronger, and negative z-scores weaker, connectivity with the ROI; further research is needed to determine their clinical implications and whether these changes denote a positive or negative outcome.

Outcome measures

Outcome measures
Measure
Sham CES Device/Treatment
n=16 Participants
Participants received a device that was identical in appearance to the true CES device and turned on and counted down with a 60 minute timer in the same manner as an active device, but delivered no stimulation. They were instructed to use the device for 60 minutes per day for 12 weeks.
True CES Device/Treatment
n=17 Participants
Participants received active stimulation using a CES device that was pre-set to a microcurrent of less than 0.5 mA and were instructed to use the device for 60 minutes per day for 12 weeks.
Change in Rs-fcMRI Connectivity Effect Size
MNI coordinates: -22 -90 -12 (Left Occipital Fusiform Gyrus)
-0.0877 Fisher-transformed z scores
Standard Deviation 0.0961
0.0786 Fisher-transformed z scores
Standard Deviation 0.1019
Change in Rs-fcMRI Connectivity Effect Size
MNI coordinates: -16 -44 -12 (Left Lingual Gyrus)
-0.1214 Fisher-transformed z scores
Standard Deviation 0.0781
0.063 Fisher-transformed z scores
Standard Deviation 0.0787
Change in Rs-fcMRI Connectivity Effect Size
MNI coordinates: +22 -44 -06 (Right Lingual Gyrus)
-0.1347 Fisher-transformed z scores
Standard Deviation 0.0964
0.0578 Fisher-transformed z scores
Standard Deviation 0.0787

SECONDARY outcome

Timeframe: baseline, 6 weeks into treatment, and 12 weeks post treatment

Tests of function (sit-to-stand, bicep curl, handgrip strength) was performed in both groups at baseline, 6 weeks, and 12 weeks following treatment. Mean difference was measured between baseline and 12 weeks. The sit-to-stand test tests how many full sit-to-stands a subject can perform within a 30 second interval.

Outcome measures

Outcome measures
Measure
Sham CES Device/Treatment
n=16 Participants
Participants received a device that was identical in appearance to the true CES device and turned on and counted down with a 60 minute timer in the same manner as an active device, but delivered no stimulation. They were instructed to use the device for 60 minutes per day for 12 weeks.
True CES Device/Treatment
n=17 Participants
Participants received active stimulation using a CES device that was pre-set to a microcurrent of less than 0.5 mA and were instructed to use the device for 60 minutes per day for 12 weeks.
Sit-to-stand
Change at 6-Week Timepoint
2.16 Change (from baseline) in repetitions
Standard Deviation 2.65
2.41 Change (from baseline) in repetitions
Standard Deviation 2.83
Sit-to-stand
Change at 12-Week Timepoint
2.13 Change (from baseline) in repetitions
Standard Deviation 2.06
3.12 Change (from baseline) in repetitions
Standard Deviation 2.93

SECONDARY outcome

Timeframe: baseline, 6 weeks into treatment, and 12 weeks post treatment

Tests of function (sit-to-stand, bicep curl, handgrip strength) was performed in both groups at baseline, 6 weeks, and 12 weeks following treatment. Mean difference was measured between baseline and 12 weeks. The bicep curl tests how many full bicep curls with gender specific weights (8 pounds for male, 5 pounds for female) a subject can perform within a 30 second interval. Both arms were tested.

Outcome measures

Outcome measures
Measure
Sham CES Device/Treatment
n=16 Participants
Participants received a device that was identical in appearance to the true CES device and turned on and counted down with a 60 minute timer in the same manner as an active device, but delivered no stimulation. They were instructed to use the device for 60 minutes per day for 12 weeks.
True CES Device/Treatment
n=17 Participants
Participants received active stimulation using a CES device that was pre-set to a microcurrent of less than 0.5 mA and were instructed to use the device for 60 minutes per day for 12 weeks.
Bicep-curl
Change at 6-Week Timepoint (Left Arm)
2.00 Change (from baseline) in repetitions
Standard Deviation 4.00
3.41 Change (from baseline) in repetitions
Standard Deviation 4.86
Bicep-curl
Change at 6-Week Timepoint (Right Arm)
2.56 Change (from baseline) in repetitions
Standard Deviation 3.38
2.53 Change (from baseline) in repetitions
Standard Deviation 4.37
Bicep-curl
Change at 12-Week Timepoint (Left Arm)
3.81 Change (from baseline) in repetitions
Standard Deviation 4.86
4.12 Change (from baseline) in repetitions
Standard Deviation 4.47
Bicep-curl
Change at 12-Week Timepoint (Right Arm)
3.19 Change (from baseline) in repetitions
Standard Deviation 4.56
3.94 Change (from baseline) in repetitions
Standard Deviation 4.13

SECONDARY outcome

Timeframe: baseline, 6 weeks into treatment, and 12 weeks post treatment

Tests of function (sit-to-stand, bicep curl, handgrip strength) was performed in both groups at baseline, 6 weeks, and 12 weeks following treatment. Mean difference was measured between baseline and 12 weeks. The handgrip strength test uses a dynamometer to gauge the pressure that a subject can apply with their handgrip. Both hands were tested.

Outcome measures

Outcome measures
Measure
Sham CES Device/Treatment
n=16 Participants
Participants received a device that was identical in appearance to the true CES device and turned on and counted down with a 60 minute timer in the same manner as an active device, but delivered no stimulation. They were instructed to use the device for 60 minutes per day for 12 weeks.
True CES Device/Treatment
n=17 Participants
Participants received active stimulation using a CES device that was pre-set to a microcurrent of less than 0.5 mA and were instructed to use the device for 60 minutes per day for 12 weeks.
Handgrip Strength
Change at 6-Week Timepoint (Left Hand)
1.13 kg
Standard Deviation 5.99
-0.29 kg
Standard Deviation 7.67
Handgrip Strength
Change at 6-Week Timepoint (Right Hand)
1.52 kg
Standard Deviation 5.56
0.12 kg
Standard Deviation 6.82
Handgrip Strength
Change at 12-Week Timepoint (Left Hand)
-0.54 kg
Standard Deviation 5.23
-1.31 kg
Standard Deviation 9.42
Handgrip Strength
Change at 12-Week Timepoint (Right Hand)
0.38 kg
Standard Deviation 5.28
0.49 kg
Standard Deviation 7.44

SECONDARY outcome

Timeframe: baseline visit and 12 weeks post treatment

NIH Patient-Reported Outcomes Measurement Information System (PROMIS) measures were assessed using a validated survey created from independently validated NIH survey questions in both groups. Mean differences in T-scores were measured between the baseline visit and the 12-week visit. PROMIS measures included: PROMIS Item Bank v1.0 - Fatigue - Short Form 6a, PROMIS Item Bank v1.0 - Emotional Distress-Depression - Short Form 4a, PROMIS Item Bank v.1.0 - Emotional Distress - Anxiety- Short Form 7a. For each measure, a lower T-score represents a better clinical outcome. All of the PROMIS measures reported (Fatigue, Depression, and Anxiety) have been standardized to have a mean of 50 and an SD of 10. This standardization means that a score of 50 is the average level in the population, and any 10-point change in either direction (greater or lesser) represents one SD difference.

Outcome measures

Outcome measures
Measure
Sham CES Device/Treatment
n=16 Participants
Participants received a device that was identical in appearance to the true CES device and turned on and counted down with a 60 minute timer in the same manner as an active device, but delivered no stimulation. They were instructed to use the device for 60 minutes per day for 12 weeks.
True CES Device/Treatment
n=17 Participants
Participants received active stimulation using a CES device that was pre-set to a microcurrent of less than 0.5 mA and were instructed to use the device for 60 minutes per day for 12 weeks.
PROMIS Change
PROMIS Item Bank v1.0 - Fatigue - Short Form 6a
-4.52 T-scores
Standard Deviation 7.97 • Interval 0.0 to 0.0
-2.61 T-scores
Standard Deviation 6.06 • Interval -0.17 to -0.03
PROMIS Change
PROMIS Item Bank v1.0 - Emotional Distress-Depression - Short Form 4a
-1.51 T-scores
Standard Deviation 7.65 • Interval 0.0 to 0.0
-2.33 T-scores
Standard Deviation 7.45 • Interval -0.35 to -0.11
PROMIS Change
PROMIS Item Bank v.1.0 - Emotional Distress - Anxiety- Short Form 7a
-3.11 T-scores
Standard Deviation 8.68
-1.57 T-scores
Standard Deviation 6.02

Adverse Events

True CES Device/Treatment

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Sham CES Device/Treatment

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Anna Woodbury

Atlanta VA Healthcare System, Decatur, GA

Phone: (404) 277-9390

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place